Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 112

1.

Mass Cytometry Discovers Two Discrete Subsets of CD39-Treg Which Discriminate MGUS From Multiple Myeloma.

Marsh-Wakefield F, Kruzins A, McGuire HM, Yang S, Bryant C, Fazekas de St Groth B, Nassif N, Byrne SN, Gibson J, Brown C, Larsen S, McCulloch D, Boyle R, Clark G, Joshua D, Ho PJ, Vuckovic S.

Front Immunol. 2019 Aug 2;10:1596. doi: 10.3389/fimmu.2019.01596. eCollection 2019.

2.

Family History, Reproductive, and Lifestyle Risk Factors for Fibroadenoma and Breast Cancer.

Li J, Humphreys K, Ho PJ, Eriksson M, Darai-Ramqvist E, Lindström LS, Hall P, Czene K.

JNCI Cancer Spectr. 2018 Dec 10;2(3):pky051. doi: 10.1093/jncics/pky051. eCollection 2018 Jul.

3.

CD300f epitopes are specific targets for acute myeloid leukemia with monocytic differentiation.

Abadir E, Gasiorowski RE, Lai K, Kupresanin F, Romano A, Silveira PA, Lo TH, Fromm PD, Kennerson ML, Iland HJ, Ho PJ, Hogarth PM, Bradstock K, Hart DNJ, Clark GJ.

Mol Oncol. 2019 Jul 23. doi: 10.1002/1878-0261.12549. [Epub ahead of print]

4.

The genetic interplay between body mass index, breast size and breast cancer risk: a Mendelian randomization analysis.

Ooi BNS, Loh H, Ho PJ, Milne RL, Giles G, Gao C, Kraft P, John EM, Swerdlow A, Brenner H, Wu AH, Haiman C, Evans DG, Zheng W, Fasching PA, Castelao JE, Kwong A, Shen X, Czene K, Hall P, Dunning A, Easton D, Hartman M, Li J.

Int J Epidemiol. 2019 Jun 1;48(3):781-794. doi: 10.1093/ije/dyz124.

5.

Renal Impairment at Diagnosis in Myeloma: Patient Characteristics, Treatment, and Impact on Outcomes. Results From the Australia and New Zealand Myeloma and Related Diseases Registry.

Ho PJ, Moore EM, McQuilten ZK, Wellard C, Bergin K, Augustson B, Blacklock H, Harrison SJ, Horvath N, King T, Mollee P, Quach H, Reid C, Rosengarten B, Walker P, Wood EM, Spencer A.

Clin Lymphoma Myeloma Leuk. 2019 Aug;19(8):e415-e424. doi: 10.1016/j.clml.2019.05.010. Epub 2019 May 16.

PMID:
31208889
6.

Handling ties in continuous outcomes for confounder adjustment with rank-ordered logit and its application to ordinal outcomes.

Ning Y, Tan CS, Maraki A, Ho PJ, Hodgins S, Comasco E, Nilsson KW, Wagner P, Khoo EY, Tai ES, Kao SL, Hartman M, Reilly M, Støer NC.

Stat Methods Med Res. 2019 Apr 3:962280219837656. doi: 10.1177/0962280219837656. [Epub ahead of print]

PMID:
30943882
7.

Factors associated with false-positive mammography at first screen in an Asian population.

Ho PJ, Bok CM, Ishak HMM, Lim LY, Liu J, Wong FY, Chia KS, Tan MH, Chay WY, Hartman M, Li J.

PLoS One. 2019 Mar 11;14(3):e0213615. doi: 10.1371/journal.pone.0213615. eCollection 2019.

8.

Comparison of self-reported and register-based hospital medical data on comorbidities in women.

Ho PJ, Tan CS, Shawon SR, Eriksson M, Lim LY, Miao H, Png E, Chia KS, Hartman M, Ludvigsson JF, Czene K, Hall P, Li J.

Sci Rep. 2019 Mar 5;9(1):3527. doi: 10.1038/s41598-019-40072-0.

9.

Three-dimensional optical trapping and orientation of microparticles for coherent X-ray diffraction imaging.

Gao Y, Harder R, Southworth SH, Guest JR, Huang X, Yan Z, Ocola LE, Yifat Y, Sule N, Ho PJ, Pelton M, Scherer NF, Young L.

Proc Natl Acad Sci U S A. 2019 Feb 14. pii: 201720785. doi: 10.1073/pnas.1720785116. [Epub ahead of print]

10.

Lenalidomide-related Progressive Multifocal Leukoencephalopathy: A Case Report and Review of Drug-related Cases in Multiple Myeloma.

Anderson S, Kiernan M, Ho PJ.

Clin Lymphoma Myeloma Leuk. 2019 Apr;19(4):e169-e171. doi: 10.1016/j.clml.2018.12.021. Epub 2019 Jan 3. No abstract available.

PMID:
30704932
11.

Evaluation of Prophylactic Heparin Dosage Strategies and Risk Factors for Venous Thromboembolism in the Critically Ill Patient.

Reynolds PM, Van Matre ET, Wright GC, McQueen RB, Burnham EL, Ho PJM, Moss M, Vandivier RW, Kiser TH; Colorado Pulmonary Outcomes Research Group (CPOR).

Pharmacotherapy. 2019 Mar;39(3):232-241. doi: 10.1002/phar.2212. Epub 2019 Jan 21.

PMID:
30592541
12.

Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma.

Schuster SJ, Bishop MR, Tam CS, Waller EK, Borchmann P, McGuirk JP, Jäger U, Jaglowski S, Andreadis C, Westin JR, Fleury I, Bachanova V, Foley SR, Ho PJ, Mielke S, Magenau JM, Holte H, Pantano S, Pacaud LB, Awasthi R, Chu J, Anak Ö, Salles G, Maziarz RT; JULIET Investigators.

N Engl J Med. 2019 Jan 3;380(1):45-56. doi: 10.1056/NEJMoa1804980. Epub 2018 Dec 1.

PMID:
30501490
13.

Pharmacokinetics and Exposure-Response Analyses of Daratumumab in Combination Therapy Regimens for Patients with Multiple Myeloma.

Xu XS, Dimopoulos MA, Sonneveld P, Ho PJ, Belch A, Leiba M, Capra M, Gomez D, Medvedova E, Iida S, Min CK, Schecter J, Jansson R, Zhang L, Sun YN, Clemens PL.

Adv Ther. 2018 Nov;35(11):1859-1872. doi: 10.1007/s12325-018-0815-9. Epub 2018 Oct 29.

14.

Daratumumab plus lenalidomide and dexamethasone versus lenalidomide and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of POLLUX.

Dimopoulos MA, San-Miguel J, Belch A, White D, Benboubker L, Cook G, Leiba M, Morton J, Ho PJ, Kim K, Takezako N, Moreau P, Kaufman JL, Sutherland HJ, Lalancette M, Magen H, Iida S, Kim JS, Prince HM, Cochrane T, Oriol A, Bahlis NJ, Chari A, O'Rourke L, Wu K, Schecter JM, Casneuf T, Chiu C, Soong D, Sasser AK, Khokhar NZ, Avet-Loiseau H, Usmani SZ.

Haematologica. 2018 Dec;103(12):2088-2096. doi: 10.3324/haematol.2018.194282. Epub 2018 Sep 20.

15.

Health-related quality of life in Asian patients with breast cancer: a systematic review.

Ho PJ, Gernaat SAM, Hartman M, Verkooijen HM.

BMJ Open. 2018 Apr 20;8(4):e020512. doi: 10.1136/bmjopen-2017-020512. Review.

16.

Gene Therapy in Patients with Transfusion-Dependent β-Thalassemia.

Thompson AA, Walters MC, Kwiatkowski J, Rasko JEJ, Ribeil JA, Hongeng S, Magrin E, Schiller GJ, Payen E, Semeraro M, Moshous D, Lefrere F, Puy H, Bourget P, Magnani A, Caccavelli L, Diana JS, Suarez F, Monpoux F, Brousse V, Poirot C, Brouzes C, Meritet JF, Pondarré C, Beuzard Y, Chrétien S, Lefebvre T, Teachey DT, Anurathapan U, Ho PJ, von Kalle C, Kletzel M, Vichinsky E, Soni S, Veres G, Negre O, Ross RW, Davidson D, Petrusich A, Sandler L, Asmal M, Hermine O, De Montalembert M, Hacein-Bey-Abina S, Blanche S, Leboulch P, Cavazzana M.

N Engl J Med. 2018 Apr 19;378(16):1479-1493. doi: 10.1056/NEJMoa1705342.

17.

A blood dendritic cell vaccine for acute myeloid leukemia expands anti-tumor T cell responses at remission.

Hsu JL, Bryant CE, Papadimitrious MS, Kong B, Gasiorowski RE, Orellana D, McGuire HM, Groth BFS, Joshua DE, Ho PJ, Larsen S, Iland HJ, Gibson J, Clark GJ, Fromm PD, Hart DN.

Oncoimmunology. 2018 Jan 25;7(4):e1419114. doi: 10.1080/2162402X.2017.1419114. eCollection 2018.

18.

Associations between workability and patient-reported physical, psychological and social outcomes in breast cancer survivors: a cross-sectional study.

Ho PJ, Hartman M, Gernaat SAM, Cook AR, Lee SC, Hupkens L, Verkooijen HM.

Support Care Cancer. 2018 Aug;26(8):2815-2824. doi: 10.1007/s00520-018-4132-2. Epub 2018 Mar 6.

PMID:
29511953
19.

Determinants of satisfaction with cosmetic outcome in breast cancer survivors: A cross-sectional study.

Ho PJ, Hartman M, Young-Afat DA, Gernaat SAM, Lee SC, Verkooijen HM.

PLoS One. 2018 Feb 21;13(2):e0193099. doi: 10.1371/journal.pone.0193099. eCollection 2018.

20.

Determinants of breast size in Asian women.

Lim LY, Ho PJ, Liu J, Chay WY, Tan MH, Hartman M, Li J.

Sci Rep. 2018 Jan 19;8(1):1201. doi: 10.1038/s41598-018-19437-4.

21.

'Real-world' Australian experience of pomalidomide for relapsed and refractory myeloma.

Scott A, Weber N, Tiley C, Taylor K, Taper J, Harrison S, Chan KL, Stark R, Lee C, Morris K, Ho PJ, Dodds A, Ramanathan S, Ramakrishna R, Watson AM, Auguston B, Kwok F, Quach H, Warburton P, Rowlings P, Mollee P.

Leuk Lymphoma. 2018 Jun;59(6):1514-1516. doi: 10.1080/10428194.2017.1387911. Epub 2017 Oct 12. No abstract available.

PMID:
29022836
22.

MED resulting from recessively inherited mutations in the gene encoding calcium-activated nucleotidase CANT1.

Balasubramanian K, Li B, Krakow D, Nevarez L, Ho PJ, Ainsworth JA, Nickerson DA, Bamshad MJ, Immken L, Lachman RS, Cohn DH.

Am J Med Genet A. 2017 Sep;173(9):2415-2421. doi: 10.1002/ajmg.a.38349. Epub 2017 Jul 25.

23.

Risk of death from cardiovascular disease following breast cancer: a systematic review.

Gernaat SAM, Ho PJ, Rijnberg N, Emaus MJ, Baak LM, Hartman M, Grobbee DE, Verkooijen HM.

Breast Cancer Res Treat. 2017 Aug;164(3):537-555. doi: 10.1007/s10549-017-4282-9. Epub 2017 May 13. Review.

24.

Risk of death from cardiovascular disease following breast cancer in Southeast Asia: a prospective cohort study.

Gernaat SAM, Ho PJ, Rijnberg N, Lee SC, Lim SH, Yap YS, Grobbee DE, Hartman M, Verkooijen HM.

Sci Rep. 2017 May 2;7(1):1365. doi: 10.1038/s41598-017-01540-7.

25.

Pharmacokinetics and safety of carfilzomib in patients with relapsed multiple myeloma and end-stage renal disease (ESRD): an open-label, single-arm, phase I study.

Quach H, White D, Spencer A, Ho PJ, Bhutani D, White M, Inamdar S, Morris C, Ou Y, Gyger M.

Cancer Chemother Pharmacol. 2017 Jun;79(6):1067-1076. doi: 10.1007/s00280-017-3287-8. Epub 2017 Apr 19.

26.

A case-based discussion of clinical problems in the management of patients treated with ruxolitinib for myelofibrosis.

Ho PJ, Bajel A, Burbury K, Dunlop L, Durrant S, Forsyth C, Perkins AC, Ross DM.

Intern Med J. 2017 Mar;47(3):262-268. doi: 10.1111/imj.13341.

PMID:
28260257
27.

The T Cell in Myeloma.

Joshua D, Suen H, Brown R, Bryant C, Ho PJ, Hart D, Gibson J.

Clin Lymphoma Myeloma Leuk. 2016 Oct;16(10):537-542. doi: 10.1016/j.clml.2016.08.003. Epub 2016 Aug 10. Review.

PMID:
27601001
28.

Cardiac iron load and function in transfused patients treated with deferasirox (the MILE study).

Ho PJ, Tay L, Teo J, Marlton P, Grigg A, St Pierre T, Brown G, Badcock CA, Traficante R, Gervasio OL, Bowden DK.

Eur J Haematol. 2017 Feb;98(2):97-105. doi: 10.1111/ejh.12793. Epub 2016 Sep 20.

PMID:
27537786
29.

Dabigatran approaching the realm of heparin-induced thrombocytopenia.

Ho PJ, Siordia JA.

Blood Res. 2016 Jun;51(2):77-87. doi: 10.5045/br.2016.51.2.77. Epub 2016 Jun 23. Review.

30.

Hetero-site-specific X-ray pump-probe spectroscopy for femtosecond intramolecular dynamics.

Picón A, Lehmann CS, Bostedt C, Rudenko A, Marinelli A, Osipov T, Rolles D, Berrah N, Bomme C, Bucher M, Doumy G, Erk B, Ferguson KR, Gorkhover T, Ho PJ, Kanter EP, Krässig B, Krzywinski J, Lutman AA, March AM, Moonshiram D, Ray D, Young L, Pratt ST, Southworth SH.

Nat Commun. 2016 May 23;7:11652. doi: 10.1038/ncomms11652.

31.

Multiple myeloma causes clonal T-cell immunosenescence: identification of potential novel targets for promoting tumour immunity and implications for checkpoint blockade.

Suen H, Brown R, Yang S, Weatherburn C, Ho PJ, Woodland N, Nassif N, Barbaro P, Bryant C, Hart D, Gibson J, Joshua D.

Leukemia. 2016 Aug;30(8):1716-24. doi: 10.1038/leu.2016.84. Epub 2016 Apr 22.

PMID:
27102208
32.

Haemoglobin disorders in Australia: where are we now and where will we be in the future?

Crighton G, Wood E, Scarborough R, Ho PJ, Bowden D.

Intern Med J. 2016 Jul;46(7):770-9. doi: 10.1111/imj.13084. Review.

PMID:
27040044
33.

A CD2 high-expressing stress-resistant human plasmacytoid dendritic-cell subset.

Bryant C, Fromm PD, Kupresanin F, Clark G, Lee K, Clarke C, Silveira PA, Suen H, Brown R, Newman E, Cunningham I, Ho PJ, Gibson J, Bradstock K, Joshua D, Hart DNj.

Immunol Cell Biol. 2016 May;94(5):447-57. doi: 10.1038/icb.2015.116. Epub 2016 Jan 21.

PMID:
26791160
34.

Practical management of myelofibrosis with ruxolitinib.

Ho PJ, Marlton P, Tam C, Stevenson W, Ritchie D, Bird R, Dunlop LC, Durrant S, Ross DM.

Intern Med J. 2015 Dec;45(12):1221-30. doi: 10.1111/imj.12921. Review.

PMID:
26648193
35.

The failure of immune checkpoint blockade in multiple myeloma with PD-1 inhibitors in a phase 1 study.

Suen H, Brown R, Yang S, Ho PJ, Gibson J, Joshua D.

Leukemia. 2015 Jul;29(7):1621-2. doi: 10.1038/leu.2015.104. Epub 2015 May 19. No abstract available.

PMID:
25987102
36.

Using digital polymerase chain reaction to detect minimal residual disease in myeloma by identifying FGFR3 up-regulation.

McAuliffe S, Brown R, Catalano A, Ho PJ, Nassif N, Woodland N, Hart D, Weatherburn C, Yang S, Suen H, Paul C, Joshua D, Gibson J.

Leuk Lymphoma. 2015;56(9):2714-6. doi: 10.3109/10428194.2014.1003061. Epub 2015 Feb 17. No abstract available.

PMID:
25651422
37.

Spot urine estimations are equivalent to 24-hour urine assessments of urine protein excretion for predicting clinical outcomes.

Teo BW, Loh PT, Wong WK, Ho PJ, Choi KP, Toh QC, Xu H, Saw S, Lau T, Sethi S, Lee EJ.

Int J Nephrol. 2015;2015:156484. doi: 10.1155/2015/156484. Epub 2015 Jan 8.

38.

Theoretical tracking of resonance-enhanced multiple ionization pathways in X-ray free-electron laser pulses.

Ho PJ, Bostedt C, Schorb S, Young L.

Phys Rev Lett. 2014 Dec 19;113(25):253001. Epub 2014 Dec 18.

PMID:
25554879
39.

Management of systemic AL amyloidosis: recommendations of the Myeloma Foundation of Australia Medical and Scientific Advisory Group.

Weber N, Mollee P, Augustson B, Brown R, Catley L, Gibson J, Harrison S, Ho PJ, Horvath N, Jaksic W, Joshua D, Quach H, Roberts AW, Spencer A, Szer J, Talaulikar D, To B, Zannettino A, Prince HM.

Intern Med J. 2015 Apr;45(4):371-82. doi: 10.1111/imj.12566. Review.

PMID:
25169210
40.

Phospho-flow detection of constitutive and cytokine-induced pSTAT3/5, pAKT and pERK expression highlights novel prognostic biomarkers for patients with multiple myeloma.

Brown R, Yang S, Weatherburn C, Gibson J, Ho PJ, Suen H, Hart D, Joshua D.

Leukemia. 2015 Feb;29(2):483-90. doi: 10.1038/leu.2014.204. Epub 2014 Jul 3.

PMID:
24990616
41.

Myeloid derived suppressor cells are numerically, functionally and phenotypically different in patients with multiple myeloma.

Favaloro J, Liyadipitiya T, Brown R, Yang S, Suen H, Woodland N, Nassif N, Hart D, Fromm P, Weatherburn C, Gibson J, Ho PJ, Joshua D.

Leuk Lymphoma. 2014 Dec;55(12):2893-900. doi: 10.3109/10428194.2014.904511. Epub 2014 May 12.

PMID:
24625328
42.
43.

Excellent outcomes for adolescents and adults with acute lymphoblastic leukemia and lymphoma without allogeneic stem cell transplant: the FRALLE-93 pediatric protocol.

Hocking J, Schwarer AP, Gasiorowski R, Patil S, Avery S, Gibson J, Iland H, Ho PJ, Joshua D, Muirhead J, Lai H, Irving I.

Leuk Lymphoma. 2014 Dec;55(12):2801-7. doi: 10.3109/10428194.2014.894191. Epub 2014 Mar 19.

PMID:
24528220
44.

Long-term survival in multiple myeloma is associated with a distinct immunological profile, which includes proliferative cytotoxic T-cell clones and a favourable Treg/Th17 balance.

Bryant C, Suen H, Brown R, Yang S, Favaloro J, Aklilu E, Gibson J, Ho PJ, Iland H, Fromm P, Woodland N, Nassif N, Hart D, Joshua DE.

Blood Cancer J. 2013 Sep 13;3:e148. doi: 10.1038/bcj.2013.34.

45.

Myeloma skews regulatory T and pro-inflammatory T helper 17 cell balance in favor of a suppressive state.

Favaloro J, Brown R, Aklilu E, Yang S, Suen H, Hart D, Fromm P, Gibson J, Khoo L, Ho PJ, Joshua D.

Leuk Lymphoma. 2014 May;55(5):1090-8. doi: 10.3109/10428194.2013.825905. Epub 2013 Aug 28.

PMID:
23865833
46.

Health of adults living with a clinically significant haemoglobinopathy in New South Wales, Australia.

Crowther HJ, Lindeman R, Ho PJ, Allen E, Waite C, Matthews S, Jobburn K, Teo J, Day S, Seldon M, Rosenfeld D, Kerridge I.

Intern Med J. 2013 Oct;43(10):1103-10. doi: 10.1111/imj.12231. Erratum in: Intern Med J. 2014 Feb;44(2):212.

PMID:
23834206
47.

Three-dimensionally ordered macroporous Cu2O/Ni inverse opal electrodes for electrochemical supercapacitors.

Deng MJ, Song CZ, Ho PJ, Wang CC, Chen JM, Lu KT.

Phys Chem Chem Phys. 2013 May 28;15(20):7479-83. doi: 10.1039/c3cp51472b. Epub 2013 Apr 22.

PMID:
23608896
48.

Trogocytosis generates acquired regulatory T cells adding further complexity to the dysfunctional immune response in multiple myeloma.

Brown R, Suen H, Favaloro J, Yang S, Ho PJ, Gibson J, Joshua D.

Oncoimmunology. 2012 Dec 1;1(9):1658-1660.

49.

Role of JNK and p38 MAPK in Taiwanin A-induced cell death.

Ho PJ, Chou CK, Yeh SF.

Life Sci. 2012 Dec 17;91(25-26):1358-65. doi: 10.1016/j.lfs.2012.10.007. Epub 2012 Nov 2.

PMID:
23123629
50.

H2O2 accumulation mediates differentiation capacity alteration, but not proliferative decline, in senescent human fetal mesenchymal stem cells.

Ho PJ, Yen ML, Tang BC, Chen CT, Yen BL.

Antioxid Redox Signal. 2013 May 20;18(15):1895-905. doi: 10.1089/ars.2012.4692. Epub 2012 Dec 20.

Supplemental Content

Support Center